Monopar Therapeutics

$6.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-6.42%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MNPR and other stocks, options, and ETFs commission-free!

About MNPR

Monopar Therapeutics Inc. Common Stock, also called Monopar Therapeutics, is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL. The listed name for MNPR is Monopar Therapeutics Inc. Common Stock.

CEO
Chandler Drew Robinson
Employees
7
Headquarters
Wilmette, Illinois
Founded
2014
Market Cap
68.70M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
32.46K
High Today
$7.01
Low Today
$6.55
Open Price
$7.00
Volume
23.39K
52 Week High
$20.50
52 Week Low
$4.28

Collections

MNPR Earnings

-$0.15
-$0.10
-$0.05
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 26, Pre-Market

You May Also Like

PPBT
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure